Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)

Abstract

EGP-2, also known as Ep-CAM, is expressed at high levels on the surface of most carcinomas and is therefore considered an attractive target for anticancer strategies. To explore the mechanisms regulating the expression of EGP-2, sequences 3.4 kb upstream of the transcription start site were isolated and assayed for their ability to control the expression of the EGP-2 cDNA, the green fluorescent protein, the luciferase reporter gene and the thymidine kinase and cytosine deaminase suicide genes. Expression of these chimeric constructs as assessed in a range of different cell lines was restricted to cell lines expressing EGP-2. In addition, only cells expressing EGP-2 were sensitive for gancyclovir after being transiently transfected with EGP-2 promoter-driven thymidine kinase. Deletion analyses defined 687 bp upstream as the basic proximal promoter region, which could confer epithelial-specific expression to the GFP reporter gene in vitro. As these EGP-2 sequences can confer promoter activity to reporter and suicide genes in an EGP-2 restricted manner, they may be useful for gene therapy of EGP-2 expressing carcinomas.

Original languageEnglish
Pages (from-to)603-612
Number of pages10
JournalCancer Gene Therapy
Volume11
Issue number9
DOIs
Publication statusPublished - Sept-2004

Keywords

  • transcriptional targeting
  • GA733-2
  • suicide gene therapy
  • EPITHELIAL-SPECIFIC EXPRESSION
  • ADHESION MOLECULE
  • MONOCLONAL-ANTIBODIES
  • TRANSCRIPTION FACTOR
  • ANTIGEN
  • THERAPY
  • CANCER
  • CLONING
  • ELEMENT
  • FAMILY

Fingerprint

Dive into the research topics of 'Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines'. Together they form a unique fingerprint.

Cite this